• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>other >Funding global health product RD: the Portfolio-To-Impact Model (P2I) a new tool for modelling the impact of different research portfolios
【2h】

Funding global health product RD: the Portfolio-To-Impact Model (P2I) a new tool for modelling the impact of different research portfolios

机译：为全球卫生产品研发提供资金：有效期投资组合模型（P2I）这是一种用于对不同研究组合的影响进行建模的新工具

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

>Background: The Portfolio-To-Impact (P2I) Model is a novel tool, developed to estimate minimum funding needs to accelerate health product development from late stage preclinical study to phase III clinical trials, and to visualize potential product launches over time. >Methods: A mixed methods approach was used. Assumptions on development costs at each phase were based on clinical trial costs from Parexel’s R&D cost sourcebook. These were further refined and validated by interviews, with a wide variety of stakeholders from Product Development Partnerships, biopharmaceutical and diagnostic companies, and major funders of global health R&D. >Results: the tool was used to create scenarios describing the impact, in terms of products developed, of different product portfolios with funding ranging from $1 million per annum through to $500 million per annum. These scenarios for a new global financing mechanism have been previously presented in a report setting out the potential for a new fund for research and development which would assist in accelerating product development for the diseases of poverty.  >Conclusion: The P2I tool does enable a user to model different scenarios in terms of cost and number of health products launched when applied to a portfolio of health products.  The model is published as open access accompanied with a user guide.  The design allows it to be adapted and used for other health R&D portfolio analysis as described in an accompanying publication focussing on the pipeline for neglected diseases in 2017. We aim to continually refine and improve the model and we ask users to provide us with their own inputs that can help us update key parameters and assumptions.  We hope to catalyse users to adapt the model in ways that can increase its value, accuracy, and applications.
机译：>背景：“有影响力投资组合（P2I）”模型是一种新颖的工具，旨在估算最低的资金需求，以加快从晚期临床前研究到III期临床试验的健康产品开发，并可视化潜力产品随时间推出。 >方法：使用了混合方法方法。每个阶段的开发成本假设均基于Parexel研发成本资源手册中的临床试验成本。通过与来自产品开发合作伙伴，生物制药和诊断公司以及全球卫生研发的主要资助者的众多利益相关者的访谈，进一步完善和验证了这些内容。 >结果：该工具用于创建情景，描述根据产品开发对不同产品组合的影响，资金从每年100万美元到每年5亿美元不等。先前已在一份报告中介绍了新的全球筹资机制的这些情况，其中阐明了新的研究和开发基金的潜力，该基金将有助于加快针对贫困疾病的产品开发。 >结论：P2I工具的确使用户能够根据应用于健康产品组合的健康产品的成本和数量对不同的情况进行建模。该模型与用户指南一起发布为开放访问。该设计使其可以适应并用于其他卫生研发投资组合分析，如随附出版物中所述（2017年侧重于被忽视疾病的渠道）所述。我们旨在不断完善和改进该模型，并请用户向我们提供自己的模型有助于我们更新关键参数和假设的输入。我们希望促使用户以可以增加其价值，准确性和应用程序的方式来适应该模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：[email protected]

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号

OSZAR »